EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0RQE: Idorsia LTD

13 Oct 2025
LAST:

3.970

CHANGE:
 0.15		OPEN:
3.935		HIGH:
4.095		ASK:
1.192		VOLUME:
2.7M
CHG(%):
3.93		PREV:
3.820		LOW:
3.885		BID:
1.079		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Oct 253.9354.0953.8853.9702.7M
10 Oct 254.1534.2003.8003.8202.7M
09 Oct 254.7604.7904.5304.605353.2K
08 Oct 254.7004.8304.6104.700100K
07 Oct 254.3804.6904.2354.678797.1K
06 Oct 254.6504.6504.2754.352434.8K
03 Oct 254.5804.8054.4104.445333.6K
02 Oct 254.5204.5404.3554.505321.1K
01 Oct 254.3004.4654.2254.4351.19M
30 Sep 253.9154.3303.8754.283308.7K

COMPANY PROFILE

Name:Idorsia LTD
About:Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat immune-mediated disorders; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and optional license and/or research and development collaboration agreement with Neurocrine Biosciences, Inc, to to develop and commercialize ACT-709478, and/or to collaborate in a research program to discover, identify and develop novel calcium channel blocker compounds for follow-on compounds to ACT-709478. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Address:Hegenheimermattweg 91, Allschwil, Switzerland, 4123
Website:https://www.idorsia.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:4.359.7%
MA10:4.3810.3%
MA20:4.123.9%
MA50:3.3618.2%
MA100:2.8240.9%
MA200:1.93105.8%
STO9:14.85 
STO14:30.48
RSI14:53.86
WPR14:-65.94
MTM14:0.21
ROC14:0.06 
ATR:0.33 
Week High:4.8321.7%
Week Low:3.804.5%
Month High:4.8321.7%
Month Low:3.41105.8%
Year High:4.8321.7%
Year Low:0.63527.7%
Volatility:17.87 

RECENT SPLITS

Date Ratio
13 Oct 20201585-1564